Amgen Reinvests Sales Gains In R&D As Phase II MariTide Readout Approaches
Phase II Studies Failed For IL-2 Mutein, LPAR1 Agonist
Amgen’s product sales grew 24% to $8.15bn in Q3 and its gains are being reinvested in R&D and manufacturing, including for MariTide, which will report Phase II obesity data in late 2024.
